Steigerwalt R - Search Results

1

ICH S1 prospective evaluation study and weight of evidence assessments: commentary from industry representatives.

Vahle JL, Dybowski J, Graziano M, Hisada S, Lebron J, Nolte T, Steigerwalt R, Tsubota K, Sistare FD. Vahle JL, et al. Among authors: steigerwalt r. Front Toxicol. 2024 May 23;6:1377990. doi: 10.3389/ftox.2024.1377990. eCollection 2024. Front Toxicol. 2024. PMID: 38845817 Free PMC article.

2

Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.

Bassan A, Steigerwalt R, Keller D, Beilke L, Bradley PM, Bringezu F, Brock WJ, Burns-Naas LA, Chambers J, Cross K, Dorato M, Elespuru R, Fuhrer D, Hall F, Hartke J, Jahnke GD, Kluxen FM, McDuffie E, Schmidt F, Valentin JP, Woolley D, Zane D, Myatt GJ. Bassan A, et al. Among authors: steigerwalt r. Front Toxicol. 2024 Apr 5;6:1370045. doi: 10.3389/ftox.2024.1370045. eCollection 2024. Front Toxicol. 2024. PMID: 38646442 Free PMC article.

3

The Accumulative Effect of Intravenous Prostaglandin E1 over Nineteen Years to Treat the Ocular Ischemia in High Myopia Keywords: Ocular ischemia, high myopia, prostaglandin E1 (PGE1), extreme choroidal thinning Prostaglandin E1 in High Myopia.

Steigerwalt RD Jr. Steigerwalt RD Jr. Retin Cases Brief Rep. 2024 Mar 27. doi: 10.1097/ICB.0000000000001577. Online ahead of print. Retin Cases Brief Rep. 2024. PMID: 38569170

4

Visual improvement in a patient with paracentral acute middle maculopathy treated with prostaglandin E1.

Steigerwalt RDJ, Nebbioso M. Steigerwalt RDJ, et al. Drug Discov Ther. 2020;14(2):98-99. doi: 10.5582/ddt.2020.03002. Drug Discov Ther. 2020. PMID: 32378652 Free article.

5

Abnormal stereopsis and reduced retinal sensitivity in patients with retinitis pigmentosa.

Vingolo EM, Limoli PG, Steigerwalt RDJ, Carlesimo SC, Salvatore S. Vingolo EM, et al. Among authors: steigerwalt rdj. Int Ophthalmol. 2020 Jan;40(1):179-184. doi: 10.1007/s10792-019-01166-w. Epub 2019 Aug 28. Int Ophthalmol. 2020. PMID: 31463623

6

Cyclodextrin Reduces Intravenous Toxicity of a Model Compound.

Mantik P, Xie M, Wong H, La H, Steigerwalt RW, Devanaboyina U, Ganem G, Shih D, Flygare JA, Fairbrother WJ, Chakravarty P, Russell D, Fernandez GE, Narang AS. Mantik P, et al. Among authors: steigerwalt rw. J Pharm Sci. 2019 Jun;108(6):1934-1943. doi: 10.1016/j.xphs.2019.01.004. Epub 2019 Jan 11. J Pharm Sci. 2019. PMID: 30639736

7

Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids.

Steigerwalt RDJ, Limoli PG, Nebbioso M. Steigerwalt RDJ, et al. Drug Discov Ther. 2017;11(4):226-229. doi: 10.5582/ddt.2017.01034. Drug Discov Ther. 2017. PMID: 28867757 Free article.

8

An ultra-low-molecular-weight heparin, fondaparinux, to treat retinal vein occlusion.

Steigerwalt RD Jr, Pascarella A, De Angelis M, Ciucci F, Gaudenzi F. Steigerwalt RD Jr, et al. Drug Discov Ther. 2016;10(3):167-71. doi: 10.5582/ddt.2016.01037. Epub 2016 Jun 15. Drug Discov Ther. 2016. PMID: 27301712 Free article. Clinical Trial.

9

Three episodes of non-arteritic posterior ischemic optic neuropathy in the same patient treated with intravenous prostaglandin E1.

Steigerwalt RD Jr, Pascarella A, De Angelis M, Grimaldi G, Nebbioso M. Steigerwalt RD Jr, et al. Drug Discov Ther. 2016;10(3):177-80. doi: 10.5582/ddt.2016.01036. Epub 2016 Jun 15. Drug Discov Ther. 2016. PMID: 27301711 Free article.

10

Correspondence.

Steigerwalt RD Jr. Steigerwalt RD Jr. Retina. 2016 Mar;36(3):e23-4. doi: 10.1097/IAE.0000000000000989. Retina. 2016. PMID: 26900676 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters